Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo

@kevinnbass @twittmypants PCSK9 solely impacts LDL? Or is its impact much broader than LDL? "Significant reductions were also observed in triglycerides, apolipoproteins CII and CIII and the cholesterol content of very low-density, intermediate-density, a

Effect of alirocumab on specific lipoprotein non-HDL cholesterol and subfractions @PCSK9Forum https://t.co/B4QQ9Uq0tO